Skip to main content

Ligand Screening Using Enzymatic Assays

  • Protocol
  • First Online:
Structural Genomics and Drug Discovery

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1140))

  • 3005 Accesses

Abstract

An important aspect of enzymatic assays is that the effect of a ligand on enzyme activity is readily apparent and quantifiable. Enzyme-based assays are, therefore, highly amenable to high-throughput ligand screening, which profiles the effect of a panel of small molecules on a designated target. In order for enzyme assays to provide useful screening data, the kinetics, assay components, readout signal, and overall stability of the assay are optimized and adapted to the equipment prior to the screen. For the screen itself, careful consideration is given to the number of replicates, the plate layout, the compound concentration, and the details of assay assembly. Lastly, in the post-screen stages, the ligand screening data is processed and analyzed using various strategies, and the resulting preliminary hits are subjected to a series of secondary and tertiary assays to eliminate false positives and poor quality hits. The various stages of screening are described, using a viral protease, NS3/4A from Hepatitis C virus, as an example of an enzyme target.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Dove A (2007) High-throughput screening goes to school. Nat Methods 4:523–532

    Article  CAS  Google Scholar 

  2. Zheng CJ, Han LY, Yap CW et al (2006) Therapeutic targets: progress of their exploration and investigation of their characteristics. Pharmacol Rev 58:259–279

    Article  CAS  PubMed  Google Scholar 

  3. Goddard JP, Reymond JL (2004) Enzyme assays for high-throughput screening. Curr Opin Biotechnol 15:314–322

    Article  CAS  PubMed  Google Scholar 

  4. Taliani M, Bianchi E, Narjes F et al (1996) A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates. Anal Biochem 240(1):60–67

    Article  CAS  PubMed  Google Scholar 

  5. Copeland RA (2005) Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. Methods Biochem Anal 46:1–265

    PubMed  Google Scholar 

  6. Macarron R, Hertzberg RP (2011) Design and implementation of high throughput screening assays. Mol Biotechnol 3:270–285

    Article  Google Scholar 

  7. Johnston PA, Foster CA, Shun TY et al (2007) Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors. Assay Drug Dev Technol 5:319–332

    Article  CAS  PubMed  Google Scholar 

  8. Tierno MB, Johnston PA, Foster C et al (2007) Development and optimization of high-throughput in vitro protein phosphatase screening assays. Nat Protoc 2:1134–1144

    Article  CAS  PubMed  Google Scholar 

  9. Feng BY, Shoichet BK (2006) A detergent-based assay for the detection of promiscuous inhibitors. Nat Protoc 1:550–553

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lu H, England K, am Ende C et al (2009) Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity. ACS Chem Biol 4(3):221–231

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Zhang JH, Chung TDY, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4(2):67–73

    Article  CAS  PubMed  Google Scholar 

  12. Wu Z, Liu D, Sui Y (2008) Quantitative assessment of hit detection and confirmation in single and duplicate high-throughput screenings. J Biomol Screen 13(2):159–167

    Article  CAS  PubMed  Google Scholar 

  13. Malo N, Hanley JA, Cerquozzi S et al (2006) Statistical practice in high-throughput screening data analysis. Nat Biotechnol 24(2):167–175

    Article  CAS  PubMed  Google Scholar 

  14. Walters WP, Stahl MT, Murcko MA (1998) Virtual screening: an overview. Drug Discovery Today 3(4):160–178

    Article  CAS  Google Scholar 

  15. Walters WP, Namchuk M (2003) Designing screens: how to make your hits a hit. Nat Rev Drug Discov 2(4):259–266

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kiira Ratia .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this protocol

Cite this protocol

Ratia, K., Mehboob, S., Lee, H. (2014). Ligand Screening Using Enzymatic Assays. In: Anderson, W.F. (eds) Structural Genomics and Drug Discovery. Methods in Molecular Biology, vol 1140. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-0354-2_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0354-2_21

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-4939-0353-5

  • Online ISBN: 978-1-4939-0354-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics